Brief: Thermogenesis Holdings Announces That ImmuneCyte Joint Venture Receives $3 Mln Equity Investment
Jan 3 (Reuters) - Thermogenesis Holdings Inc THMO.O :
* THERMOGENESIS HOLDINGS ANNOUNCES THAT IMMUNECYTE JOINT
VENTURE
RECEIVES $3.0 MILLION EQUITY INVESTMENT
* THERMOGENESIS - INVESTOR RECEIVED 600,000 SHARES OF CLASS
A
STOCK AT $5.00/SHARE, REPRESENTING A 5.66% OWNERSHIP IN JV
* THERMOGENESIS - AFTER INVESTMENT, IMMUNECYTE IS OWNED
75.47% BY
HEALTHBANKS BIOTECH (USA), 18.87% BY CO, 5.66% BY THE PRIVATE
INSTITUTION
* THERMOGENESIS HOLDINGS - BECAUSE OF EQUITY INVESTMENT IN
IMMUNECYTE, CO' EQUITY IN JV IS NO LONGER SUBJECT TO
ANTI-DILUTION PROVISION
Source text for Eikon: ID:nPn8pYhRja
Further company coverage: THMO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Thermogenesis Holdings
See all newsThermogenesis Holdings Inc expected to post earnings of 1 cent a share - Earnings Preview
Thermogenesis Holdings Inc reports results for the quarter ended in December - Earnings Summary
Thermogenesis Holdings Inc expected to post a loss of 1 cent a share - Earnings Preview
Thermogenesis Holdings Inc expected to post a loss of 1 cent a share - Earnings Preview
Brief: Thermogenesis Holdings Says On Jan 8 Co Received Nasdaq Letter Notifying It No Longer Complies With Minimum Bid Price Requirement For Listing On Nasdaq